http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eef543a8037f69ead52129a28fc91509
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Reis-Filho |
| name | Jorge S Reis-Filho Jorge S. Reis-Filho |
| given-name | Jorge S. Jorge S |
| organization-name | 10Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Pathology (BW, RB, RK, DLM, FCG, FP, AL, PS, RSL, GJ, HYW, JSRF) Memorial Sloan Kettering Cancer Center, New York, NY 2The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; All authors: Memorial Sloan Kettering Cancer Center, New York, NY. IPATIMUP-Institute of Molecular Pathology and Immunology, University of Porto, Porto; School of Health Sciences, University of Minho, Braga From Salomão & Zoppi Associated Pathologists (Drs Pereira and Maeda), Porto, Portugal; and the Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal (Dr Reis-Filho) Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; 1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; 6Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. IPATIMUP–Institute of Molecular Pathology, University of Porto, Porto, Portugal, The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Chester Beatty Laboratories, London, United Kingdom 6Hospital of Prato, Prato, Italy. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States 1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom and Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; 2Breast Unit, Royal Marsden Hospital, London, United Kingdom; 3Department of Pathology; and 4Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; 2Breast Unit, Royal Marsden Hospital, London, United Kingdom; 3Department of Pathology; and 4Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 1Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research; Authors' Affiliations: 1Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Cancérologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee From the Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal (Drs Reis-Filho and Lopes); the School of Health Sciences, University of Minho, Braga, Portugal (Dr Reis-Filho); and the Department of Pathology, Medical Faculty and São João Hospital, Porto, Portugal (Dr Lopes) Department of Pathology, Memorial Sloan-Kettering Cancer Center The Institute of Cancer Research, London, United Kingdom 1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; 8Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; 7Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 2Department of Gynaecologic Oncology, Royal Marsden Hospital NHS Foundation Trust, 3Department of Biostatistics and 4Department of Histopathology, Royal Marsden Hospital; 5Department of Histopathology, Imperial College London, Hammersmith Hospital; and 6Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London, United Kingdom; 7University of Edinburgh Cancer Research Centre, Edinburgh; United Kingdom; 8Department of Pathology, Belfast Health and Social Care Trust; 9Department of Oncology, Belfast Health and Social Care Trust, Belfast, United Kingdom Authors' Affiliations: 1Signal Transduction Team and 2Molecular Pathology/The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom Department of Pathology, Memorial Sloan Kettering Cancer Center; New York NY USA The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK The Breakthrough Toby Robins Breast Cancer Research Centre, London, United Kingdom Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA From The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, England (Drs Reis-Filho, Fulford, and Lakhani); Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Braga, Portugal (Dr Reis-Filho); The Ludwig Institute for Cancer Research, London, England (Drs Fulford and Lakhani); and Department of Histopathology, The From the Department of Histopathology, Nottingham City Hospital National Health Service (NHS) Trust; Nottingham University, Nottingham; and the Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom 4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Pathology From the Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal. 1Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom and 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; Departments of The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, United Kingdom; Experimental Pathology, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center, New York, NY, USA 1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 8Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. From the Department of Histopathology, Nottingham City Hospital NHS Trust. Nottingham University, Nottingham, United Kingdom (Dr Rakha); and The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London, United Kingdom (Dr Reis-Filho) From the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 2Academic Department of Biochemistry, and 3Breast Unit, Royal Marsden Hospital, London, United Kingdom Authors' Affiliation: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065; Authors' Affiliations: 1Signal Transduction Team, Section of Cell and Molecular Biology, 2Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; and 3Gene and Oncogene Targeting Team, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom Authors' Affiliations: The Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom From the Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom (Drs Reis-Filho, Fulford, and Lakhani); the Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Braga, Portugal (Dr Reis-Filho); the Department of Histopathology, The Royal Marsden Hospital, London, United Kingdom (Dr Lakhani); and the Inst Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY From the Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal (Drs Reis-Filho and Schmitt); Medical Faculty, University of Porto, Porto, Portugal (Dr Schmitt); and Federal University of Paraná, Curitiba, Brazil (Dr Figueiredo) 1Memorial Sloan Kettering Cancer Center, New York, New York.; 9Department of Pathology, Weill Cornell Medical College, New York, New York. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 9Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; 2Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 8The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom Cancer Research UK Gene Function and Regulation Group; London UK 1The Breakthrough Breast Cancer Research Centre and Breakthrough Breast Cancer Research Centre Institute of Cancer Research London UK 3Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; 4Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, United Kingdom 2The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; and The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, SW3 6JB London, UK. Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; 2Breast Unit, Royal Marsden Hospital; 3Breakthrough Breast Cancer Research Unit, King's College London School of Medicine, Guy's Hospital, London, United Kingdom Universidade Federal do Paraná, Brasil Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA 4Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; and 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; 1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; 5Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. From the Department of Pathology, São João Hospital, and Medical Faculty, University of Porto, Porto, Portugal (Drs Cruz and Lopes); and IPATIMUP–Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal (Drs Reis-Filho and Lopes) The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK. 1Memorial Sloan Kettering Cancer Center, New York, New York. 1Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research and 3Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; Authors' Affiliations: Departments of 1Pathology and 2Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; 3Cancer Research UK Clinical Trials Unit, The Institute of Cancer Research, Sutton; 4Cancer Research UK London Research Institute; and 5University College London Cancer Institute, London, United Kingdom Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; and 2Breast Unit, Royal Marsden Hospital, London, United Kingdom From the Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal (Drs Reis-Filho and Lopes); and the Department of Pathology, University of Porto and Hospital São João, Porto, Portugal (Drs Paiva and Lopes) 3Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 1The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; 13Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA Authors' Affiliations: 1Signal Transduction Laboratory, Cancer Research UK, London Research Institute; 2The Breakthrough Breast Cancer Centre; 3Division of Cancer Biology, The Institute of Cancer Research, London, United Kingdom; and 4Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York Department of Pathology; Memorial Sloan Kettering Cancer Center; New York NY USA Authors' Affiliations: Departments of 1Pediatric Hematology and Oncology and 2Pharmacology, University of Bologna; 3Department of Nuclear Medicine, University of Bologna, S. Orsola Hospital, Bologna, Italy; 4Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics and 5Pediatric Oncology, The Institute of Cancer Research, Sutton, Surrey, United Kingdom; 6Department of Human Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 7Department of Organic and Industrial Chemistry, University of Parma, Parma, Italy; 8Kiel Pediatric Tumor Registry, Department of Pediatric Pathology, University of Kiel, Kiel, Germany; 9Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Chester Beatty Laboratories; and 10Department of Histopathology, Royal Marsden NHS Trust, London, United Kingdom 1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; 10Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Authors' Affiliations: 1Breast Service, Department of Surgery; Departments of 2Pathology; and 3Medicine; and the 4Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York; Authors' Affiliations: 1Breast Service, Department of Surgery; Departments of 2Pathology; and 3Medicine; and the 4Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 1The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London; 2Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, UK, SW3 6JB Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK. |
Incoming Links
Total number of triples: 448.